SAN DIEGO – At the American Association for Cancer Research (AACR) Annual Meeting 2026, the conversation around AI-driven cancer research has moved decisively past theory. Now the focus is on what’s being deployed and how to gain researchers’ and clinicians’ trust.
Fay Lin, PhD, senior editor, technology at GEN, and Jonathan D. Grinstein, PhD, North American editor at Inside Precision Medicine, discuss how AI is increasingly embedded across cancer research areas, from organoid models to pathology. Yet challenges such as data integration, longitudinal patient tracking, and clinician confidence continue to hinder its impact on patient outcomes.
Watch the full discussion below for a clearer view of the trends, tensions, and inflection points in AI shaping the future of cancer research:
